VHAM
BIAF icon

Van Hulzen Asset Management’s bioAffinity Technologies BIAF Stock Holding History

Van Hulzen Asset Management’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-534
Closed -$4.16K – 327
2025
Q1 		$4.16K Buy
+534
New +$9.79K ﹤0.01% 312

Other funds holding BIAF

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Van Hulzen Asset Management's BIAF Position: Q2 2025 in Review

Van Hulzen Asset Management sold out of bioAffinity Technologies (BIAF) in Q2 2025, closing a stake of 534 shares — an estimated $4.16K sold.

Van Hulzen Asset Management first reported a position in BIAF in Q1 2025 and held it in 1 quarter. The position peaked at $4.16K in Q1 2025. 17 funds tracked by Wall St. Rank hold BIAF as of Q2 2025.

  • Van Hulzen Asset Management reported no remaining bioAffinity Technologies position as of Q2 2025 after selling out during the quarter.
  • Van Hulzen Asset Management sold 534 bioAffinity Technologies shares in Q2 2025, an estimated $4.16K.
  • Van Hulzen Asset Management first reported a position in bioAffinity Technologies in Q1 2025 and held it in 1 quarter.
  • Van Hulzen Asset Management's bioAffinity Technologies position peaked at $4.16K in Q1 2025.
  • 17 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2025.

Based on Van Hulzen Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.